Skip to content

Study · Randomized controlled trial · n = 186 · 2013

16 results

[Application of half-dose depot long-acting triptorelin in postoperative adjuvant therapy for endometriosis].

Liu X, Zhang HX, Wang LP, Fu WP

Zhonghua yi xue za zhi1 Jan 2013Cited by 3 (Europe PMC)

PMID23570596 (opens in a new tab)PepBankPUB-23570596
Publisher pageAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postoperative endometriosis patients, all triptorelin dose groups achieved amenorrhea after the second injection.

    In plain wordsIn endometriosis patients after surgery, all triptorelin dose groups stopped menstruation after the second injection.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableAmenorrhea
    Study

    n = 186

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1.875 mg, 3.75 mg then 1.875 mg, or 3.75 mg every 28 days · intramuscularAs given in this study (human).

    Source sentences

    Summary
    Amenorrhea was effectively induced in all patients after the second injection.
    2 context sentences
    Summary · context
    A total of 186 postoperative patients with moderate or severe endometriosis received an intramuscular injection of triptorelin every 28 days for 6 times.
    Summary · context
    They were randomly divided into 3 groups, i.e. half-dose group (n = 99): 1.875 mg each time; "draw-back" group (n = 52): 3.75 mg first time, then 1.875 mg each time; and routine-dose group (n = 35): 3.75 mg each time.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In endometriosis patients, half-dose triptorelin and the draw-back regimen had similar rates of E2 below the estrogen threshold.

    In plain wordsIn endometriosis patients, half-dose triptorelin and the draw-back regimen had similar rates of estrogen suppression.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeE2 below estrogen threshold
    Study

    n = 151

    Comparator
    draw-back regimen
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1.875 mg every 28 days for 6 injections · intramuscularAs given in this study (human).

    Measurements

    E2 below estrogen threshold rate
    99%
    Half-dose
    E2 below estrogen threshold rate
    100%
    Draw-back

    Source sentences

    Summary
    There was no significant difference in the rate of serum E2 level at Day 28 of every injection below the upper limit of "estrogen threshold (110 - 146 pmol/L)" not stimulating ectopic endometrium proliferation among half-dose group, "draw-back" group and routine-dose group (99% vs 100% and 99.0%, P > 0.05),
    2 context sentences
    Summary · context
    A total of 186 postoperative patients with moderate or severe endometriosis received an intramuscular injection of triptorelin every 28 days for 6 times.
    Summary · context
    They were randomly divided into 3 groups, i.e. half-dose group (n = 99): 1.875 mg each time; "draw-back" group (n = 52): 3.75 mg first time, then 1.875 mg each time; and routine-dose group (n = 35): 3.75 mg each time.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In endometriosis patients with E2 below 110 pmol/L, half-dose triptorelin produced a lower proportion below 37 pmol/L than the draw-back regimen after injections 2-5.

    In plain wordsAmong patients with E2 below 110 pmol/L, fewer reached E2 below 37 pmol/L with half-dose triptorelin than the draw-back regimen.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseE2 below 37 pmol/L after injections 2-5
    Study

    n = 151

    Comparator
    draw-back regimen
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1.875 mg every 28 days for 6 injections · intramuscularAs given in this study (human).

    Measurements

    E2 below 37 pmol/L within E2 below 110 pmol/L
    69%
    Half-dose
    E2 below 37 pmol/L within E2 below 110 pmol/L
    79%
    Draw-back

    Source sentences

    Summary
    the percentage of E2 < 37 pmol/L in E2 < 110 pmol/L in half-dose group was significantly lower than that in "draw-back" and routine-dose groups after 2-5(th) injection (69% vs 79% and 85%, P < 0.01),
    2 context sentences
    Summary · context
    A total of 186 postoperative patients with moderate or severe endometriosis received an intramuscular injection of triptorelin every 28 days for 6 times.
    Summary · context
    They were randomly divided into 3 groups, i.e. half-dose group (n = 99): 1.875 mg each time; "draw-back" group (n = 52): 3.75 mg first time, then 1.875 mg each time; and routine-dose group (n = 35): 3.75 mg each time.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In endometriosis patients, half-dose triptorelin and the draw-back regimen provided similar pelvic pain relief at the first returning menstruation.

    In plain wordsIn endometriosis patients, half-dose triptorelin and the draw-back regimen provided similar pain relief when periods returned.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changePelvic pain relief
    Study

    n = 151

    Comparator
    draw-back regimen
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    1.875 mg every 28 days for 6 injections · intramuscularAs given in this study (human).

    Source sentences

    Summary
    No significant difference existed in the rate of pelvic pain relief during the first returning menstruation and the recurrence rate of endometriosis within 1 year postoperation among three groups (both P > 0.05).
    2 context sentences
    Summary · context
    A total of 186 postoperative patients with moderate or severe endometriosis received an intramuscular injection of triptorelin every 28 days for 6 times.
    Summary · context
    They were randomly divided into 3 groups, i.e. half-dose group (n = 99): 1.875 mg each time; "draw-back" group (n = 52): 3.75 mg first time, then 1.875 mg each time; and routine-dose group (n = 35): 3.75 mg each time.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In endometriosis patients, recurrence within 1 year after surgery was similar with half-dose triptorelin and the draw-back regimen.

    In plain wordsIn endometriosis patients, recurrence within 1 year was similar with half-dose triptorelin and the draw-back regimen.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeEndometriosis recurrence
    Study

    n = 151

    Comparator
    draw-back regimen
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1.875 mg every 28 days for 6 injections · intramuscularAs given in this study (human).

    Source sentences

    Summary
    No significant difference existed in the rate of pelvic pain relief during the first returning menstruation and the recurrence rate of endometriosis within 1 year postoperation among three groups (both P > 0.05).
    2 context sentences
    Summary · context
    A total of 186 postoperative patients with moderate or severe endometriosis received an intramuscular injection of triptorelin every 28 days for 6 times.
    Summary · context
    They were randomly divided into 3 groups, i.e. half-dose group (n = 99): 1.875 mg each time; "draw-back" group (n = 52): 3.75 mg first time, then 1.875 mg each time; and routine-dose group (n = 35): 3.75 mg each time.
  6. 06HumanRandomized controlled trialSafety outcome

    In endometriosis patients, half-dose triptorelin reduced menopausal syndrome versus the draw-back regimen.

    In plain wordsIn endometriosis patients, half-dose triptorelin caused fewer menopause symptoms than the draw-back regimen.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseMenopausal syndrome
    Study

    n = 151

    Comparator
    draw-back regimen
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    1.875 mg every 28 days for 6 injections · intramuscularAs given in this study (human).

    Source sentences

    Summary
    However, the incidences of menopausal syndrome and severe menopausal syndrome in half-dose group were significantly lower than those in "draw-back" and routine-dose groups (both P < 0.01).
    2 context sentences
    Summary · context
    A total of 186 postoperative patients with moderate or severe endometriosis received an intramuscular injection of triptorelin every 28 days for 6 times.
    Summary · context
    They were randomly divided into 3 groups, i.e. half-dose group (n = 99): 1.875 mg each time; "draw-back" group (n = 52): 3.75 mg first time, then 1.875 mg each time; and routine-dose group (n = 35): 3.75 mg each time.
  7. 07HumanRandomized controlled trialSafety outcome

    In endometriosis patients, half-dose triptorelin reduced severe menopausal syndrome versus the draw-back regimen.

    In plain wordsIn endometriosis patients, half-dose triptorelin caused fewer severe menopause symptoms than the draw-back regimen.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseSevere menopausal syndrome
    Study

    n = 151

    Comparator
    draw-back regimen
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    1.875 mg every 28 days for 6 injections · intramuscularAs given in this study (human).

    Source sentences

    Summary
    However, the incidences of menopausal syndrome and severe menopausal syndrome in half-dose group were significantly lower than those in "draw-back" and routine-dose groups (both P < 0.01).
    2 context sentences
    Summary · context
    A total of 186 postoperative patients with moderate or severe endometriosis received an intramuscular injection of triptorelin every 28 days for 6 times.
    Summary · context
    They were randomly divided into 3 groups, i.e. half-dose group (n = 99): 1.875 mg each time; "draw-back" group (n = 52): 3.75 mg first time, then 1.875 mg each time; and routine-dose group (n = 35): 3.75 mg each time.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In endometriosis patients, half-dose and routine-dose triptorelin had similar rates of E2 below the estrogen threshold.

    In plain wordsIn endometriosis patients, half-dose and routine-dose triptorelin had similar rates of estrogen suppression.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeE2 below estrogen threshold
    Study

    n = 134

    Comparator
    routine-dose triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1.875 mg every 28 days for 6 injections · intramuscularAs given in this study (human).

    Measurements

    E2 below estrogen threshold rate
    99%
    Half-dose
    E2 below estrogen threshold rate
    99%
    Routine-dose

    Source sentences

    Summary
    There was no significant difference in the rate of serum E2 level at Day 28 of every injection below the upper limit of "estrogen threshold (110 - 146 pmol/L)" not stimulating ectopic endometrium proliferation among half-dose group, "draw-back" group and routine-dose group (99% vs 100% and 99.0%, P > 0.05),
    2 context sentences
    Summary · context
    A total of 186 postoperative patients with moderate or severe endometriosis received an intramuscular injection of triptorelin every 28 days for 6 times.
    Summary · context
    They were randomly divided into 3 groups, i.e. half-dose group (n = 99): 1.875 mg each time; "draw-back" group (n = 52): 3.75 mg first time, then 1.875 mg each time; and routine-dose group (n = 35): 3.75 mg each time.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In endometriosis patients with E2 below 110 pmol/L, half-dose triptorelin produced a lower proportion below 37 pmol/L than routine-dose treatment after injections 2-5.

    In plain wordsAmong patients with E2 below 110 pmol/L, fewer reached E2 below 37 pmol/L with half-dose triptorelin than routine-dose treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseE2 below 37 pmol/L after injections 2-5
    Study

    n = 134

    Comparator
    routine-dose triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1.875 mg every 28 days for 6 injections · intramuscularAs given in this study (human).

    Measurements

    E2 below 37 pmol/L within E2 below 110 pmol/L
    69%
    Half-dose
    E2 below 37 pmol/L within E2 below 110 pmol/L
    85%
    Routine-dose

    Source sentences

    Summary
    the percentage of E2 < 37 pmol/L in E2 < 110 pmol/L in half-dose group was significantly lower than that in "draw-back" and routine-dose groups after 2-5(th) injection (69% vs 79% and 85%, P < 0.01),
    2 context sentences
    Summary · context
    A total of 186 postoperative patients with moderate or severe endometriosis received an intramuscular injection of triptorelin every 28 days for 6 times.
    Summary · context
    They were randomly divided into 3 groups, i.e. half-dose group (n = 99): 1.875 mg each time; "draw-back" group (n = 52): 3.75 mg first time, then 1.875 mg each time; and routine-dose group (n = 35): 3.75 mg each time.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In endometriosis patients, half-dose and routine-dose triptorelin had similar profound E2 suppression rates after the first injection.

    In plain wordsIn endometriosis patients, profound estrogen suppression after the first injection was similar with half-dose and routine-dose triptorelin.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeE2 suppression after first injection
    Study

    n = 134

    Comparator
    routine-dose triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1.875 mg every 28 days for 6 injections · intramuscularAs given in this study (human).

    Measurements

    E2 below 37 pmol/L within E2 below 110 pmol/L after first injection
    71%
    Half-dose
    E2 below 37 pmol/L within E2 below 110 pmol/L after first injection
    73%
    Routine-dose

    Source sentences

    Summary
    but there was no significant difference after first half-dose and routine-dose injection (71% vs 73%, P > 0.05).
    2 context sentences
    Summary · context
    A total of 186 postoperative patients with moderate or severe endometriosis received an intramuscular injection of triptorelin every 28 days for 6 times.
    Summary · context
    They were randomly divided into 3 groups, i.e. half-dose group (n = 99): 1.875 mg each time; "draw-back" group (n = 52): 3.75 mg first time, then 1.875 mg each time; and routine-dose group (n = 35): 3.75 mg each time.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In endometriosis patients, half-dose and routine-dose triptorelin provided similar pelvic pain relief at the first returning menstruation.

    In plain wordsIn endometriosis patients, half-dose and routine-dose triptorelin provided similar pain relief when periods returned.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changePelvic pain relief
    Study

    n = 134

    Comparator
    routine-dose triptorelin
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    1.875 mg every 28 days for 6 injections · intramuscularAs given in this study (human).

    Source sentences

    Summary
    No significant difference existed in the rate of pelvic pain relief during the first returning menstruation and the recurrence rate of endometriosis within 1 year postoperation among three groups (both P > 0.05).
    2 context sentences
    Summary · context
    A total of 186 postoperative patients with moderate or severe endometriosis received an intramuscular injection of triptorelin every 28 days for 6 times.
    Summary · context
    They were randomly divided into 3 groups, i.e. half-dose group (n = 99): 1.875 mg each time; "draw-back" group (n = 52): 3.75 mg first time, then 1.875 mg each time; and routine-dose group (n = 35): 3.75 mg each time.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In endometriosis patients, recurrence within 1 year after surgery was similar with half-dose and routine-dose triptorelin.

    In plain wordsIn endometriosis patients, recurrence within 1 year was similar with half-dose and routine-dose triptorelin.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeEndometriosis recurrence
    Study

    n = 134

    Comparator
    routine-dose triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1.875 mg every 28 days for 6 injections · intramuscularAs given in this study (human).

    Source sentences

    Summary
    No significant difference existed in the rate of pelvic pain relief during the first returning menstruation and the recurrence rate of endometriosis within 1 year postoperation among three groups (both P > 0.05).
    2 context sentences
    Summary · context
    A total of 186 postoperative patients with moderate or severe endometriosis received an intramuscular injection of triptorelin every 28 days for 6 times.
    Summary · context
    They were randomly divided into 3 groups, i.e. half-dose group (n = 99): 1.875 mg each time; "draw-back" group (n = 52): 3.75 mg first time, then 1.875 mg each time; and routine-dose group (n = 35): 3.75 mg each time.
  13. 13HumanRandomized controlled trialSafety outcome

    In endometriosis patients, half-dose triptorelin reduced menopausal syndrome versus routine-dose triptorelin.

    In plain wordsIn endometriosis patients, half-dose triptorelin caused fewer menopause symptoms than routine-dose triptorelin.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseMenopausal syndrome
    Study

    n = 134

    Comparator
    routine-dose triptorelin
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    1.875 mg every 28 days for 6 injections · intramuscularAs given in this study (human).

    Source sentences

    Summary
    However, the incidences of menopausal syndrome and severe menopausal syndrome in half-dose group were significantly lower than those in "draw-back" and routine-dose groups (both P < 0.01).
    2 context sentences
    Summary · context
    A total of 186 postoperative patients with moderate or severe endometriosis received an intramuscular injection of triptorelin every 28 days for 6 times.
    Summary · context
    They were randomly divided into 3 groups, i.e. half-dose group (n = 99): 1.875 mg each time; "draw-back" group (n = 52): 3.75 mg first time, then 1.875 mg each time; and routine-dose group (n = 35): 3.75 mg each time.
  14. 14HumanRandomized controlled trialSafety outcome

    In endometriosis patients, half-dose triptorelin reduced severe menopausal syndrome versus routine-dose triptorelin.

    In plain wordsIn endometriosis patients, half-dose triptorelin caused fewer severe menopause symptoms than routine-dose triptorelin.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseSevere menopausal syndrome
    Study

    n = 134

    Comparator
    routine-dose triptorelin
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    1.875 mg every 28 days for 6 injections · intramuscularAs given in this study (human).

    Source sentences

    Summary
    However, the incidences of menopausal syndrome and severe menopausal syndrome in half-dose group were significantly lower than those in "draw-back" and routine-dose groups (both P < 0.01).
    2 context sentences
    Summary · context
    A total of 186 postoperative patients with moderate or severe endometriosis received an intramuscular injection of triptorelin every 28 days for 6 times.
    Summary · context
    They were randomly divided into 3 groups, i.e. half-dose group (n = 99): 1.875 mg each time; "draw-back" group (n = 52): 3.75 mg first time, then 1.875 mg each time; and routine-dose group (n = 35): 3.75 mg each time.
  15. 15HumanRandomized controlled trialSafety outcome

    In endometriosis patients, half-dose triptorelin reduced treatment incompletion from severe menopause symptoms versus the other dose groups.

    In plain wordsIn endometriosis patients, half-dose triptorelin reduced treatment incompletion from severe menopause symptoms compared with the other dose groups.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseTreatment incompletion due to severe menopausal syndrome
    Study

    n: not reported in source

    Comparator
    draw-back and routine-dose groups
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    1.875 mg every 28 days for 6 injections · intramuscularAs given in this study (human).

    Source sentences

    Summary
    And the incompletion rate of six-time drug for severe menopause syndrome was also significantly lower (P < 0.05) while the completion rate of six-time drug use in half-dose group was significantly higher (P < 0.05).
    2 context sentences
    Summary · context
    A total of 186 postoperative patients with moderate or severe endometriosis received an intramuscular injection of triptorelin every 28 days for 6 times.
    Summary · context
    They were randomly divided into 3 groups, i.e. half-dose group (n = 99): 1.875 mg each time; "draw-back" group (n = 52): 3.75 mg first time, then 1.875 mg each time; and routine-dose group (n = 35): 3.75 mg each time.
  16. 16HumanRandomized controlled trialOther

    In endometriosis patients, half-dose triptorelin increased completion of all injections versus the other dose groups.

    In plain wordsIn endometriosis patients, half-dose triptorelin increased treatment completion compared with the other dose groups.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseTreatment completion
    Study

    n: not reported in source

    Comparator
    draw-back and routine-dose groups
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1.875 mg every 28 days for 6 injections · intramuscularAs given in this study (human).

    Source sentences

    Summary
    And the incompletion rate of six-time drug for severe menopause syndrome was also significantly lower (P < 0.05) while the completion rate of six-time drug use in half-dose group was significantly higher (P < 0.05).
    2 context sentences
    Summary · context
    A total of 186 postoperative patients with moderate or severe endometriosis received an intramuscular injection of triptorelin every 28 days for 6 times.
    Summary · context
    They were randomly divided into 3 groups, i.e. half-dose group (n = 99): 1.875 mg each time; "draw-back" group (n = 52): 3.75 mg first time, then 1.875 mg each time; and routine-dose group (n = 35): 3.75 mg each time.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.